Citation Impact
Citing Papers
Antidepressant Drug Effects and Depression Severity
2010 Standout
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
2005 Standout
How to perform a meta-analysis with R: a practical tutorial
2019 Standout
Chlorpromazine versus placebo for schizophrenia
2007
Intracerebral infusion of (+)-AJ76 and (+)-UH232: effects on dopamine release and metabolism in vivo
1994 StandoutNobel
Childhood and Adolescent Depression: A Review of the Past 10 Years. Part I
1996 Standout
The selective dopamine antagonist properties of BRL 34778: a novel substituted benzamide
1988 StandoutNobel
The adolescent brain and age-related behavioral manifestations
2000 Standout
The dopamine D3-receptor: A postsynaptic receptor inhibitory on rat locomotor activity
1993 StandoutNobel
The efficacy of drug treatments for dysthymia: a systematic review and meta-analysis
1999
An Open Trial of Clozapine in 11 Adolescents with Childhood-Onset Schizophrenia
1994
Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia
2000 StandoutNobel
Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics
1990 StandoutNature
Psychosis as a State of Aberrant Salience: A Framework Linking Biology, Phenomenology, and Pharmacology in Schizophrenia
2002 Standout
Synthesis and Release of Dopamine in Rat Brain: Comparison Between Substantia Nigra Pars Compacta, Pars Reticulata, and Striatum
1989 StandoutNobel
The Physiology, Signaling, and Pharmacology of Dopamine Receptors
2011 Standout
The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway
2009 Standout
The dopamine D3 receptor and autoreceptor preferring antagonists (+)-AJ76 and (+)-UH232; a microdialysis study
1993 StandoutNobel
Antipsychotic Properties of the Partial Dopamine Agonist (−)-3-(3-Hydroxyphenyl)-N-n-Propylpiperidine (Preclamol) in Schizophrenia
1998 StandoutNobel
In Vitro Metabolism of Haloperidol and Sila-Haloperidol: New Metabolic Pathways Resulting from Carbon/Silicon Exchange
2009
Haloperidol versus placebo for schizophrenia
2001
Antipsychotic-Induced Weight Gain: A Comprehensive Research Synthesis
1999 Standout
Neurotransmitter aberrations in schizophrenia: New perspectives and therapeutic implications
1997 StandoutNobel
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
2013 Standout
5 Amidines and Guanidines in Medicinal Chemistry
1993
A comparative study of haloperidol and chlorpromazine in terms of clinical effects and therapeutic reversal with benztropine in schizophrenia. Theoretical implications for potency differences among neuroleptics
1975
Chlorpromazine versus placebo for schizophrenia
2014
Sexually differentiated actions of 3-PPP enantiomers on prolactin secretion
1986 StandoutNobel
Social Support as a Moderator of Life Stress
1976 Standout
MECHANISM OF THE ANTIPSYCHOTIC EFFECT IN THE TREATMENT OF ACUTE SCHIZOPHRENIA
1978
Ciclindole and flucindole: Novel tetrahydrocarbazolamine neuroleptics
1984
Rapid Changes in Brain Benzodiazepine Receptors After Experimental Seizures
1978 Science
Urinary and brain beta-carboline-3-carboxylates as potent inhibitors of brain benzodiazepine receptors.
1980 Standout
Dopaminergic neurons: An in vivo system for measuring drug interactions with presynaptic receptors
1976
The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia
1987 Standout
Mechanistic Studies on the Cu-Catalyzed Three-Component Reactions of Sulfonyl Azides, 1-Alkynes and Amines, Alcohols, or Water: Dichotomy via a Common Pathway
2008 StandoutNobel
Additions to Metal-Activated Organonitriles
2002 Standout
Dopamine release and metabolism in awake rats after systemic neuroleptics as studied by trans-striatal dialysis
1985
The behavioral pharmacology of butaclamol hydrochloride (AY-23,028), a new potent neuroleptic drug
1975
Dopamine receptors in human and calf brains, using [3H]apomorphine and an antipsychotic drug.
1976
A glutamatergic deficiency model of schizophrenia
1999 StandoutNobel
Haloperidol versus chlorpromazine for schizophrenia
2008
Dopamine autoreceptors and the effects of drugs on locomotion and dopamine synthesis
1985 StandoutNobel
Neuroleptic-induced acute dyskinesias in squirrel monkeys: Correlation with propensity to cause extrapyramidal side effects
1980
A New Depression Scale Designed to be Sensitive to Change
1979 Standout
Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats.
1988 Standout
Multiple receptors for dopamine
1979 StandoutNature
Dopamine-receptor agonists: Mechanisms underlying autoreceptor selectivity
1985 StandoutNobel
Dopamine in schizophrenia: a review and reconceptualization
1991 Standout
Dopamine receptors involved in prolactin secretion pharmacologically characterized by means of 3-PPP enantiomers
1983 StandoutNobel
Does dopamine play a role in schizophrenia?
1977 StandoutNobel
(+)- and (−)-3-PPP exhibit different intrinsic activity at striatal dopamine autoreceptors controlling dopamine synthesis
1984 StandoutNobel
3-PPP, a new centrally acting DA-receptor agonist with selectivity for autoreceptors
1981 StandoutNobel
The Efficacy of Antidepressant Drugs
1974
Loxapine and clozapine decrease serotonin (S2) but do not elevate dopamine (D2) receptor numbers in the rat brain
1984
Haloperidol versus placebo for schizophrenia
2013
Antipsychotic Drugs, Neurotransmitters, and Schizophrenia
1978 StandoutNobel
Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
1976 StandoutScience
Dopamine receptor agonists: Mechanisms underlying autoreceptor selectivity II. Theoretical considerations
1985 StandoutNobel
Clinical Evaluation of Sulpiride in Schizophrenic Patients ‐ A Double‐blind Comparison with Chlorpromazine
1984
Increased baseline occupancy of D 2 receptors by dopamine in schizophrenia
2000 Standout
Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency
1980
Dropping out of treatment: A critical review.
1975
Dopaminergic receptors in the anterior pituitary gland. Correlation of [3H]dihydroergocryptine binding with the dopaminergic control of prolactin release.
1978 StandoutNobel
Brain receptors for antipsychotic drugs and dopamine: direct binding assays.
1975
The Catalytic Asymmetric Fischer Indolization
2011 StandoutNobel
Sila-Trifluperidol, a Silicon Analogue of the Dopamine (D2) Receptor Antagonist Trifluperidol: Synthesis and Pharmacological Characterization
2010
Effect of Hypericum perforatum (St John's Wort) in Major Depressive Disorder
2002 Standout
The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence
1985 Standout
Pharmacotherapy of Disorders of Adolescents
1993
Industry sponsorship and research outcome
2017 Standout
(+)-AJ 76 and (+)-UH 232: Central stimulants acting as preferential dopamine autoreceptor antagonists
1986 StandoutNobel
Lack of functional evidence for the involvement of sigma opiate receptors in the actions of the 3-PPP enantiomers on central dopaminergic systems: Discrepancies between and observations
1985 StandoutNobel
Drug Treatment of Anxiety and Depression in Detoxified Alcoholic Patients
1973
Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design
2011 Standout
Works of Gallant Dm being referenced
A CONTROLLED EVALUATION OF TRIFLUPERIDOL: A NEW POTENT PSYCHOPHARMACOLOGIC AGENT.
1963
BL-KR140: a controlled evaluation in chronic schizophrenic patients previously stabilized on chlorpromazine.
1967
A six-month controlled evaluation of metronidazole (Flagyl) in chronic alcoholic patients.
1968
Assessment of antipsychotic activity of an unique agent: SU-23397.
1975
COMPARISON OF HALOPERIDOL, TRIFLUPERIDOL, AND CHLORPROMAZINE IN ACUTE SCHIZOPHRENIC PATIENTS.
1964
JB-8181: ANTIDEPRESSANT ACTIVITY IN OUTPATIENTS.
1964
Molindone: a crossover evaluation of capsule and tablet formulations in severely ill schizophrenic patients.
1973
A controlled evaluation of U-23,807A in the neurotic depressive syndrome.
1967
Effects of two butyrophenone compounds on acute schizophrenic patients: speculation on the neurophysiologic sites of action.
1967
A controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients.
1976
Butaclamol hydrochloride (AY-23,028): an early evaluation in severely ill schizophrenics.
1975
Sulpiride: evaluation of antipsychotic activity in schizophrenic patients.
1977
Amoxapine: a double-blind evaluation of antidepressant activity.
1973
Effects of diazepam on three per second spike and wave discharges.
1967
CL-67,772: a preliminary evaluation of a potential antidepressant compound. Animal and human correlations.
1969
Cinanserin (SQ. 10,643): a preliminary evaluation in chronic schizophrenic patients.
1968